Inicio・Lista de Acciones・PTC Therapeutics Inc

PTC Therapeutics Inc

Cerrado

SectorSanidad

73.06 3.5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

72.06

Máximo

73.3

Métricas clave
By Trading Economics
Ingresos	86M 83M
Ventas	88M 361M
P/B Media del Sector	7.597 68.51
BPA	0.92
Margen de beneficios	23.16
Empleados	991
EBITDA	198M 162M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+34.55% upside

Dividendos
By Acuity
Próximas Ganancias	3 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-603M 5.7B
Apertura anterior	69.56
Cierre anterior	73.06

Noticias sobre sentimiento de mercado

By Acuity

55%

45%

264 / 340 Clasificación en Healthcare

PTC Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6 ago 2026, 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5 ago 2026, 19:26 UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4 ago 2026, 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3 ago 2026, 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31 jul 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30 jul 2026, 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29 jul 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28 jul 2026, 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27 jul 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22 jul 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21 jul 2026, 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20 jul 2026, 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Comparación entre iguales

Cambio de precio

PTC Therapeutics Inc previsión

Precio Objetivo

By TipRanks

34.55% repunte

Estimación a 12 Meses

Media 98.64 USD 34.55%

Máximo 130 USD

Mínimo 70 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para PTC Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para PTC Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

264 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.